Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes

Michael Einar Røder; Heidi Storgaard; Jørgen Rungby; Filip Krag Knop; Tina Vilsbøll

Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes

Translated title of the contribution: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes

Michael Einar Røder, Heidi Storgaard, Jørgen Rungby, Filip Krag Knop, Tina Vilsbøll

2 Citations (Scopus)

Abstract

The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.

Translated title of the contribution	Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes
Original language	Danish
Article number	V05160310
Journal	Ugeskrift for Laeger
Volume	178
Issue number	26
Pages (from-to)	2461-64
ISSN	0041-5782
Publication status	Published - 26 Dec 2016

Keywords

English Abstract
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://ugeskriftet.dk/videnskab/sodium-glucose-cotransporter-sglt-2-inhibitorer-til-patienter-med-type-2-diabetes

Cite this

@article{3d33f6ef6b134d94be627f0c53a1c88c,

title = "Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes",

abstract = "The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.",

keywords = "English Abstract, Journal Article",

author = "R{\o}der, {Michael Einar} and Heidi Storgaard and J{\o}rgen Rungby and Knop, {Filip Krag} and Tina Vilsb{\o}ll",

year = "2016",

month = dec,

day = "26",

language = "Dansk",

volume = "178",

pages = "2461--64",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "26",

}

TY - JOUR

T1 - Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes

AU - Røder, Michael Einar

AU - Storgaard, Heidi

AU - Rungby, Jørgen

AU - Knop, Filip Krag

AU - Vilsbøll, Tina

PY - 2016/12/26

Y1 - 2016/12/26

N2 - The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.

AB - The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.

KW - English Abstract

KW - Journal Article

M3 - Tidsskriftartikel

C2 - 27649712

SN - 0041-5782

VL - 178

SP - 2461

EP - 2464

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 26

M1 - V05160310

ER -

Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this